跳至主要内容
临床试验/CTRI/2021/02/031407
CTRI/2021/02/031407已完成2 期

Randomized double arm Clinical Trial to evaluate the efficacy of Siddha Varmam Therapy (SVT) among Type II Diabetes Mellitus patients attending Madhumegam Special OPD, SCRU, Tirupati

Central council for Research in Siddha1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年2月22日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
1.Efficacy of Siddha Varmam therapy on Type II Diabetes Mellitus patients in reducing the FBS, PPBS, HbA1c at baseline, 30, 60, 90 days of treatment.

研究概览

简要总结

InSiddha system of medicine varmam is one unique method of physical manipulationused for various ailments. In recent years there are many clinical trialsconducted on Varmam therapy to treat diseases such as osteoarthritis, periarthritis,cervical spondylosis, lumbar spondylosis, autism.But still now no attempts were made to prove its effect in Diabetes. This studyaims to validate the SVT in Type II Diabetes Mellitus patients. The objectiveof the study is to evaluate the hypoglycemic activity of Siddha varmam therapy(SVT) among Type II diabetes Mellitus patients in reducing the FBS, PPBS, HbA1c.SVT manipulation done by trained siddha varmam doctor on three days once forthe period of 3 months. The outcome of the study is assessed by Efficacyof Siddha Varmam therapy on Type II Diabetes Mellitus patients in reducing theFBS, PPBS, HbA1c at baseline, 90 days of treatment. There are 15 patientsrecruited in Arm 1, 15 patients recruited in arm-2. The study completed itsrecruitment on 02-08-2023.

研究设计

研究类型
Interventional
分配方式
Other
盲法
Not Applicable

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Subjects in Age between 30-60 years of both gender
  • Patients having Fasting blood sugar ranging above 100 and below 200 mg/dl
  • HbA1C ranging above 5.5% below 7.5%.

排除标准

  • Subjects with the age below 30 years and above 60 years are to be excluded from the study.
  • Pregnant women and planning to be pregnant within six months and lactating mother.
  • Known case of i.
  • Malignancy ii.
  • Accelerated Hypertension iii.
  • Coronary artery disease iv.
  • CNS disorders v.
  • Type I Diabetes mellitus vi.
  • Acute infection or fever vii.
  • Chronic viral hepatitis or HIV-infection.

结局指标

主要结局

1.Efficacy of Siddha Varmam therapy on Type II Diabetes Mellitus patients in reducing the FBS, PPBS, HbA1c at baseline, 30, 60, 90 days of treatment.

时间窗: 9 months

次要结局

  • 1. Safety of Siddha Varmam therapy on Type II Diabetes Mellitus patients is assessed by comparing Liver function Test and Renal function Test at baseline, 30, 60, 90 days of treatment.(2. Siddha diagnostic tool is validated and tested at baseline, 30, 60, 90 days of treatment.)

研究者

发起方
Central council for Research in Siddha
申办方类型
Research institution

研究点 (1)

Loading locations...

相似试验